Header cover image

Swedish (OMX) Pharma Industry Analysis

UpdatedAug 05, 2024
DataAggregated Company Financials
Companies32
  • 7D-2.4%
  • 3M26.9%
  • 1Y74.8%
  • YTD17.0%

Over the last 7 days, the Pharma industry has dropped 2.4%, driven by a pullback from Camurus of 3.6%. On the other hand Infant Bacterial Therapeutics is actually up 19%. Over the past 12 months, the industry was up 75%. As for the next few years, earnings are expected to grow by 67% per annum.

Industry Valuation and Performance

Has the Swedish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 05 Aug 2024SEK 66.7bSEK 5.6b-SEK 992,767,193.4593.9x-67.2x11.9x
Wed, 03 Jul 2024SEK 66.6bSEK 6.4b-SEK 862,463,298.6977.3x-77.2x10.5x
Fri, 31 May 2024SEK 57.8bSEK 6.4b-SEK 766,455,412.1768.9x-75.4x9.1x
Sun, 28 Apr 2024SEK 48.6bSEK 6.3b-SEK 950,949,196.2765.4x-51.1x7.7x
Tue, 26 Mar 2024SEK 52.1bSEK 6.2b-SEK 1,038,112,114.3977.6x-50.2x8.3x
Thu, 22 Feb 2024SEK 46.9bSEK 6.2b-SEK 974,265,935.1382.2x-48.1x7.5x
Sat, 20 Jan 2024SEK 68.2bSEK 9.5b-SEK 1,182,202,468.0062.3x-57.7x7.2x
Mon, 18 Dec 2023SEK 66.4bSEK 9.4b-SEK 1,184,292,161.0063.3x-56.1x7x
Wed, 15 Nov 2023SEK 58.2bSEK 9.5b-SEK 1,251,356,587.0090x-46.5x6.1x
Fri, 13 Oct 2023SEK 51.3bSEK 9.2b-SEK 1,181,414,633.00108.5x-43.4x5.6x
Sun, 10 Sep 2023SEK 50.8bSEK 9.2b-SEK 1,177,925,858.00137.5x-43.1x5.5x
Tue, 08 Aug 2023SEK 51.0bSEK 8.9b-SEK 1,411,098,856.0084.2x-36.2x5.7x
Thu, 06 Jul 2023SEK 48.2bSEK 8.4b-SEK 1,693,605,337.0073.2x-28.5x5.8x
Sat, 03 Jun 2023SEK 47.9bSEK 8.4b-SEK 1,609,645,369.0076.5x-29.8x5.7x
Mon, 01 May 2023SEK 47.1bSEK 8.1b-SEK 1,817,383,597.0096.9x-25.9x5.8x
Wed, 29 Mar 2023SEK 44.0bSEK 8.0b-SEK 1,793,573,955.0083x-24.5x5.5x
Fri, 24 Feb 2023SEK 45.1bSEK 7.6b-SEK 2,020,097,232.00220.5x-22.3x5.9x
Sun, 22 Jan 2023SEK 48.9bSEK 7.3b-SEK 1,938,336,904.00278.2x-25.2x6.7x
Tue, 20 Dec 2022SEK 49.1bSEK 7.3b-SEK 1,876,118,602.00273.2x-26.2x6.7x
Thu, 17 Nov 2022SEK 48.6bSEK 6.9b-SEK 1,899,423,952.0048.5x-25.6x7.1x
Sat, 15 Oct 2022SEK 49.3bSEK 7.0b-SEK 1,754,682,602.0047x-28.1x7.1x
Mon, 12 Sep 2022SEK 52.7bSEK 7.0b-SEK 1,737,204,557.0055.4x-30.3x7.6x
Wed, 10 Aug 2022SEK 53.2bSEK 6.9b-SEK 1,535,185,883.0041.5x-34.7x7.7x
Fri, 08 Jul 2022SEK 54.1bSEK 5.9b-SEK 1,509,116,648.0041.5x-35.9x9.1x
Sun, 05 Jun 2022SEK 54.2bSEK 5.9b-SEK 1,505,666,101.0044.6x-36x9.1x
Tue, 03 May 2022SEK 53.8bSEK 5.5b-SEK 1,351,308,728.0037.6x-39.8x9.7x
Thu, 31 Mar 2022SEK 54.4bSEK 5.4b-SEK 1,280,292,342.0039.2x-42.5x10.1x
Sat, 26 Feb 2022SEK 46.5bSEK 5.4b-SEK 1,090,445,538.0076.5x-42.7x8.7x
Mon, 24 Jan 2022SEK 49.1bSEK 5.5b-SEK 1,083,939,448.00112.1x-45.3x9x
Wed, 22 Dec 2021SEK 55.2bSEK 5.5b-SEK 1,100,338,740.00112.9x-50.2x10.1x
Fri, 19 Nov 2021SEK 59.3bSEK 5.3b-SEK 1,355,585,770.0088x-43.8x11.3x
Sun, 17 Oct 2021SEK 52.9bSEK 4.8b-SEK 1,581,702,061.00140.1x-33.4x11x
Tue, 14 Sep 2021SEK 57.5bSEK 4.8b-SEK 1,560,489,765.26153.5x-36.9x12x
Thu, 12 Aug 2021SEK 55.4bSEK 4.8b-SEK 1,412,039,942.26162.8x-39.2x11.6x
Price to Earnings Ratio

-39.2x


Total Market Cap: SEK 55.4bTotal Earnings: -SEK 1,412,039,942.26Total Revenue: SEK 4.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Pharma Industry Price to Earnings3Y Average -40.8x202220232024
Current Industry PE
  • Investors are optimistic on the Swedish Pharmaceuticals industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 8.0x is lower than the industry's current PS ratio of 11.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Revenues for these companies have grown 5.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market-4.26%
Healthcare-3.15%
Pharma-2.42%
Pharma-2.42%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
IBT B Infant Bacterial TherapeuticsSEK 117.0018.9%
+SEK 250.6m		27.5%PS22842.8x
CESSA CessatechDKK 8.008.1%
+DKK 10.5m		327.8%PB7.4x
CLBIO Corline BiomedicalSEK 13.306.0%
+SEK 16.1m		-19.1%PS9.3x
PILA Pila PharmaSEK 6.545.5%
+SEK 9.2m		186.8%PS121.3x
ZICC ZiccumSEK 5.948.0%
+SEK 7.0m		-32.3%PS10.6x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

CESSA

DKK 8.00

Cessatech

7D

8.1%

1Y

327.8%

Is Cessatech (NGM:CESSA) In A Good Position To Invest In Growth?

Aug 03
Is Cessatech (NGM:CESSA) In A Good Position To Invest In Growth?

ENZY

SEK 1.87

Enzymatica

7D

-9.2%

1Y

-33.8%

ORX

SEK 15.08

Orexo

7D

-5.8%

1Y

-16.8%

Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

Aug 02
Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

IBT B

SEK 117.00

Infant Bacterial Therapeutics

7D

18.9%

1Y

27.5%

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

SECARE

SEK 45.00

Swedencare

7D

-3.6%

1Y

-4.7%

ACUC

SEK 0.88

AcuCort

7D

4.8%

1Y

-20.0%

DICOT

SEK 0.27

Dicot Pharma

7D

-7.5%

1Y

75.3%

CSMED

DKK 12.85

CS Medica

7D

-22.5%

1Y

76.8%

CAMX

SEK 646.50

Camurus

7D

-3.6%

1Y

122.6%

FLERIE

SEK 44.80

Flerie

7D

-3.2%

1Y

n/a

NEWBRY

SEK 3.76

Newbury Pharmaceuticals

7D

5.6%

1Y

-7.8%

MOB

SEK 33.78

Moberg Pharma

7D

-3.7%

1Y

122.2%

CLBIO

SEK 13.30

Corline Biomedical

7D

6.0%

1Y

-19.1%

ZICC

SEK 5.94

Ziccum

7D

8.0%

1Y

-32.3%

PILA

SEK 6.54

Pila Pharma

7D

5.5%

1Y

186.8%

EMPLI

SEK 0.47

Emplicure

7D

9.3%

1Y

-68.5%